Summit Therapeutics Inc. (SMMT) - Dilution Analysis

10-Q filing | 775.5M shares outstanding

10-Q filing | 743.4M shares outstanding

10-Q filing | 742.6M shares outstanding

10-Q filing | 738.1M shares outstanding

10-K filing | 718.5M shares outstanding

10-Q filing | 726.7M shares outstanding

10-Q filing | 707.9M shares outstanding

10-Q filing | 701.8M shares outstanding

S-3 filing: Summit Therapeutics Inc. is offering common stock, preferred stock, debt securities, depositary shares, subscription rights, purchase contracts and units, with an aggregate offering price not to exceed $450,000,000. The selling stockholder may offer and sell up to 2,976,190 shares of Common Stock from time to time.

10-K filing | 701.7M shares outstanding

10-Q filing | 697.7M shares outstanding

10-Q filing | 697.7M shares outstanding

10-Q filing | 697.7M shares outstanding

8-K filing: Summit Therapeutics Inc. registered for resale 10,000,000 shares of Common Stock issued on January 17, 2023 to Akeso, Inc. and 9,346,434 and 373,857 shares of Common Stock issued in December 2022 to Robert Duggan and the Mahkam Zanganeh Revocable Trust, respectively.

S-3 filing: This is an S-3 filing for a shelf offering of Summit Therapeutics Inc. common stock, allowing selling stockholders to resell up to 19,720,291 shares.

10-K filing | 697.7M shares outstanding

8-K filing: Summit Therapeutics Inc. announced the closing and final results of its rights offering, resulting in the issuance of approximately 476.2 million shares of common stock at a price of $1.05 per share, with aggregate gross proceeds of $500 million, bringing the total shares outstanding to approximately 697.7 million. ($500.0M proceeds)

8-K filing: Summit Therapeutics Inc. announced the record date for its previously announced rights offering, which will be available to stockholders of record as of February 6, 2023, to purchase up to 476,190,476 shares of common stock at a price per share equal to the lesser of $1.05 per share or the volume weighted-average price through March 1, 2023, with expected gross proceeds of up to $500 million. ($500.0M proceeds)

8-K filing: Summit Therapeutics Inc. announces a rights offering available to holders of common stock to purchase up to 476,190,476 shares at a price per share equal to the lesser of $1.05 or the volume weighted-average price, with potential gross proceeds of up to $500 million, less expenses. ($500.0M proceeds)

S-3/A filing: Summit Therapeutics Inc. is distributing at no charge to the holders of their common stock, par value $0.01 per share, non-transferable subscription rights to purchase up to 476,190,476 shares of common stock at the Initial Price with an aggregate offering value of up to $500,000,000.

8-K filing: Summit Therapeutics issued 10 million shares of common stock to Akeso in lieu of cash as part of their Collaboration and License Agreement, and Amendment No. 2 to the Restated Certificate of Incorporation was filed to increase the number of authorized shares of common stock by 650,000,000.

S-3 filing: Summit Therapeutics Inc. is distributing at no charge to the holders of our common stock, par value $0.01 per share, non-transferable subscription rights to purchase up to 476,190,476 shares of common stock with an aggregate offering value of up to $500,000,000.

8-K filing: Summit Therapeutics Inc. entered into a Collaboration and License Agreement with Akeso, Inc. and its affiliates, and also issued unsecured promissory notes to Robert W. Duggan and Dr. Maky Zanganeh.

10-Q filing | 201.3M shares outstanding

8-K filing: Summit Therapeutics Inc. closed its rights offering on August 15, 2022, issuing 103,092,783 shares of common stock at $0.97 per share, resulting in gross proceeds of $100 million and 201,215,139 shares outstanding. ($100.0M proceeds)

10-Q filing | 99.7M shares outstanding

8-K filing: Summit Therapeutics Inc. closed its rights offering, with eligible stockholders purchasing approximately 103 million shares of common stock at $0.97 per share, resulting in aggregate gross proceeds of $100 million and approximately 201 million shares outstanding. ($100.0M proceeds)

10-Q filing | 98.1M shares outstanding

10-K filing | 92.2M shares outstanding

10-Q filing | 97.5M shares outstanding

10-Q filing | 90.7M shares outstanding

10-Q filing | 97.2M shares outstanding

10-K filing | 82.9M shares outstanding

S-3 filing: Summit Therapeutics Inc. is offering 63,859,111 shares of common stock and 5,474,522 shares of common stock issuable upon exercise of warrants.

10-Q filing | 82.3M shares outstanding

8-K filing: Summit Therapeutics Inc. completed a private placement on November 6, 2020, issuing and selling 14,071,856 shares of common stock to Robert W. Duggan and 898,204 shares to Polar Capital Funds plc and Mahkam Zanganeh Revocable Trust, at a price of $3.34 per share, for an aggregate purchase price of $50 million.

8-K filing: Summit Therapeutics Inc. entered into a Securities Purchase Agreement with its CEO and Executive Chairman, Robert W. Duggan, to issue and sell up to 14,970,060 shares of common stock at $3.34 per share in a private placement, for up to approximately $50 million. ($50.0M proceeds)

20-F filing | 335.9M shares outstanding